Assembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer
October 28 2019 - 8:00AM
Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and diseases associated with the
microbiome, today announced the appointment of Thomas J. Russo as
Chief Financial Officer. Mr. Russo brings 25 years of experience in
the biotechnology and pharmaceutical industry, spanning finance and
operations (including commercial planning and manufacturing), as
well as equity research.
“I have worked closely with Tom for many years and have seen him
in action. He has excelled in building highly integrated and
functional financial infrastructures, and that experience will
support our future growth as we continue to advance our HBV and
microbiome programs,” said John McHutchison, AO, MD, Chief
Executive Officer and President. “With his deep knowledge of the
biotechnology industry, finances, operations, global forecasting
and the capital markets, he will be an important addition to our
leadership team, particularly as our core inhibitors move into
later stage clinical development for the treatment of HBV.”
“I am enthusiastic to join Assembly’s leadership team and to
pursue transformative and potentially curable treatments for HBV
infection, as has been done with Hepatitis C,” said Mr. Russo. “The
unmet need throughout the world is enormous, and the science and
team at Assembly are exceptional, so I look forward to helping
provide the financial and operational support to position our
strategy and programs for success.”
Mr. Russo joins Assembly from Gilead, where he spent seven years
in finance and commercial operations roles, including Vice
President, Head of Commercial Finance. In this capacity, he
supported a $20-30 billion revenue business and multi-billion
dollar budget across North America, Europe, Asia and emerging
markets. He served as a strategic partner, helping drive the
planning, reporting and analysis for commercial operations, and
managing a staff of finance leaders and professionals supporting
Gilead’s business around the world. Previously, Mr. Russo was
Equity Research Senior Analyst covering biotechnology for
investment bank, Robert W. Baird & Co., Inc., where he advised
institutional investors and received recognition including WSJ Best
on the Street (2010, 2011). He also spent nine years with
Merck & Co. in roles of increasing responsibility within the
manufacturing division. Mr. Russo received a B.S. in Biological
Sciences from the University of Notre Dame and an M.B.A. from the
University of Chicago Booth School of Business. He is also a CFA
charterholder.
About Assembly BiosciencesAssembly Biosciences,
Inc. is a clinical-stage biotechnology company developing
innovative therapeutics targeting hepatitis B virus (HBV) and
diseases associated with the microbiome. The HBV program is focused
on advancing a new class of potent, oral core inhibitors that have
the potential to increase cure rates for chronically infected
patients. The microbiome program is developing novel oral live
microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP banking and production, and
targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology. For more information, visit
assemblybio.com.
Forward-Looking StatementsThe information in
this press release contains forward-looking statements regarding
future events, including statements about the clinical and
therapeutic potential of core inhibitors and advancement of our
core inhibitors into later stage clinical trials. Certain
forward-looking statements may be identified by reference to a
future period or by use of forward-looking terminology such as
“advances” and “potential.” Assembly intends such forward-looking
statements to be covered by the safe harbor provisions contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. More information
about the risks and uncertainties faced by Assembly are more fully
detailed under the heading “Risk Factors” in Assembly's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2019 filed with
the Securities and Exchange Commission. Except as required by law,
Assembly assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsAssembly Biosciences,
Inc.Investors:Lauren Glaser(415)
521-3828lglaser@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Sep 2023 to Sep 2024